BR112015007319A2 - composições e métodos para produzir glicoproteínas - Google Patents
composições e métodos para produzir glicoproteínasInfo
- Publication number
- BR112015007319A2 BR112015007319A2 BR112015007319A BR112015007319A BR112015007319A2 BR 112015007319 A2 BR112015007319 A2 BR 112015007319A2 BR 112015007319 A BR112015007319 A BR 112015007319A BR 112015007319 A BR112015007319 A BR 112015007319A BR 112015007319 A2 BR112015007319 A2 BR 112015007319A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- producing glycoproteins
- producing
- glycoproteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Abstract
resumo patente de invenção: "composições e métodos para produzir glicoproteínas". a presente descrição refere-se a métodos de produção de anticorpos com maiores níveis de glicoformas não fucosiladas por cultura de células de mamífero em meio de cultura com concentrações aumentadas de glicina em relação ao meio basal tradicional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261708554P | 2012-10-01 | 2012-10-01 | |
US61/708,554 | 2012-10-01 | ||
PCT/US2013/062410 WO2014055370A1 (en) | 2012-10-01 | 2013-09-27 | Compostions and methods for producing glycoproteins |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015007319A2 true BR112015007319A2 (pt) | 2017-08-08 |
BR112015007319B1 BR112015007319B1 (pt) | 2022-02-15 |
Family
ID=49354940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015007319-0A BR112015007319B1 (pt) | 2012-10-01 | 2013-09-27 | Método de produção de um anticorpo igg1 |
Country Status (27)
Country | Link |
---|---|
US (2) | US20150259425A1 (pt) |
EP (1) | EP2904092B1 (pt) |
JP (1) | JP6351598B2 (pt) |
KR (1) | KR102182885B1 (pt) |
CN (1) | CN104797707A (pt) |
AU (1) | AU2013327681B2 (pt) |
BR (1) | BR112015007319B1 (pt) |
CA (1) | CA2886753C (pt) |
CY (1) | CY1119602T1 (pt) |
DK (1) | DK2904092T3 (pt) |
EA (1) | EA201590550A1 (pt) |
ES (1) | ES2646594T3 (pt) |
HK (1) | HK1207394A1 (pt) |
HR (1) | HRP20171753T1 (pt) |
HU (1) | HUE034896T2 (pt) |
IL (1) | IL237916A0 (pt) |
IN (1) | IN2015DN02630A (pt) |
LT (1) | LT2904092T (pt) |
ME (1) | ME02882B (pt) |
MX (1) | MX366106B (pt) |
NO (1) | NO2760138T3 (pt) |
PL (1) | PL2904092T3 (pt) |
PT (1) | PT2904092T (pt) |
RS (1) | RS56641B1 (pt) |
SG (2) | SG10201702448WA (pt) |
SI (1) | SI2904092T1 (pt) |
WO (1) | WO2014055370A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014337263B2 (en) | 2013-10-16 | 2019-12-12 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
SG11201703446RA (en) | 2014-10-31 | 2017-05-30 | Abbvie Biotherapeutics Inc | Anti-cs1 antibodies and antibody drug conjugates |
WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
US20190048070A1 (en) * | 2016-01-06 | 2019-02-14 | Oncobiologics, Inc. | Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition |
CA3010598A1 (en) | 2016-01-06 | 2017-07-13 | Oncobiologics, Inc. | Modulation of afucosylated species in a monoclonal antibody composition |
WO2017136433A1 (en) | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
WO2017146646A1 (en) * | 2016-02-22 | 2017-08-31 | Agency For Science, Technology And Research | Cell culture medium |
CN110121359A (zh) * | 2016-11-11 | 2019-08-13 | 怀特黑德生物制剂研究所 | 人血浆培养基 |
CN111944050B (zh) * | 2020-08-19 | 2022-05-13 | 苏州普乐康医药科技有限公司 | 一种抗b7-h3抗体及其应用 |
CN113337562B (zh) * | 2021-05-24 | 2022-06-03 | 宁波人健药业集团股份有限公司 | 使用CHO细胞高效发酵生产rhCG的方法 |
CN113480632B (zh) * | 2021-07-30 | 2023-02-03 | 宁波人健药业集团股份有限公司 | 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO2002066603A2 (en) * | 2001-02-15 | 2002-08-29 | Centocor, Inc. | Chemically defined medium for cultured mammalian cells |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
JP4857259B2 (ja) | 2004-03-24 | 2012-01-18 | アボット バイオセラピューティクス コーポレイション | 癌細胞増殖を阻害するための抗α5β1抗体の使用 |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
US9056908B2 (en) | 2007-08-03 | 2015-06-16 | Abbvie Biotherapeutics Inc. | Therapeutic use of anti-tweak receptor antibodies |
-
2012
- 2012-01-12 NO NO14160512A patent/NO2760138T3/no unknown
-
2013
- 2013-09-27 PL PL13776656T patent/PL2904092T3/pl unknown
- 2013-09-27 EP EP13776656.4A patent/EP2904092B1/en active Active
- 2013-09-27 WO PCT/US2013/062410 patent/WO2014055370A1/en active Application Filing
- 2013-09-27 ES ES13776656.4T patent/ES2646594T3/es active Active
- 2013-09-27 BR BR112015007319-0A patent/BR112015007319B1/pt active IP Right Grant
- 2013-09-27 ME MEP-2017-285A patent/ME02882B/me unknown
- 2013-09-27 LT LTEP13776656.4T patent/LT2904092T/lt unknown
- 2013-09-27 RS RS20171200A patent/RS56641B1/sr unknown
- 2013-09-27 SG SG10201702448WA patent/SG10201702448WA/en unknown
- 2013-09-27 DK DK13776656.4T patent/DK2904092T3/en active
- 2013-09-27 CA CA2886753A patent/CA2886753C/en active Active
- 2013-09-27 PT PT137766564T patent/PT2904092T/pt unknown
- 2013-09-27 SI SI201330877T patent/SI2904092T1/en unknown
- 2013-09-27 JP JP2015534771A patent/JP6351598B2/ja active Active
- 2013-09-27 KR KR1020157009991A patent/KR102182885B1/ko active IP Right Grant
- 2013-09-27 MX MX2015004027A patent/MX366106B/es active IP Right Grant
- 2013-09-27 HU HUE13776656A patent/HUE034896T2/hu unknown
- 2013-09-27 CN CN201380058690.XA patent/CN104797707A/zh active Pending
- 2013-09-27 SG SG11201502339YA patent/SG11201502339YA/en unknown
- 2013-09-27 EA EA201590550A patent/EA201590550A1/ru unknown
- 2013-09-27 US US14/432,653 patent/US20150259425A1/en not_active Abandoned
- 2013-09-27 AU AU2013327681A patent/AU2013327681B2/en active Active
- 2013-09-27 IN IN2630DEN2015 patent/IN2015DN02630A/en unknown
-
2015
- 2015-03-24 IL IL237916A patent/IL237916A0/en unknown
- 2015-08-18 HK HK15108000.4A patent/HK1207394A1/xx unknown
-
2017
- 2017-02-03 US US15/424,672 patent/US20170152540A1/en not_active Abandoned
- 2017-11-14 HR HRP20171753TT patent/HRP20171753T1/hr unknown
- 2017-11-14 CY CY20171101192T patent/CY1119602T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015007319A2 (pt) | composições e métodos para produzir glicoproteínas | |
MY169935A (en) | "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof" | |
BR112016014488A2 (pt) | Meio para cultura celular | |
PH12015501837A1 (en) | Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recominbinant proteins | |
BR112013004514A2 (pt) | diferenciação das células-tronco embrionárias humanas | |
BR112014031424A2 (pt) | tratamento de células pluripotentes | |
BR112013023006A8 (pt) | formulações de suspensões não aquosas de anticorpos de alta concentração e viscosidade reduzida | |
MX355650B (es) | Produccion de proteinas en medios de cultivo de celulas libres de glutamina. | |
BR112013004616A2 (pt) | diferenciação das células tronco embrionárias humanas | |
MX2013014937A (es) | Cultivo de celulas de mamifero. | |
MY166973A (en) | Methods for reducing accumulation of lactate during culturing and method for producing polypeptide | |
MY161726A (en) | Biological methods for preparing adipic acid | |
BR112013033448A2 (pt) | células deficientes em ácido cmp-n-acetilneuramínico hidroxilase e/ou glicoproteína alfa-1,3-galactosiltransferase | |
MX345399B (es) | Metodo de cultivo de celulas animales. | |
EP2582792A4 (en) | HEART OF CARDIOMYOCYTES WITH DIALYSATED SERUM | |
BR112015021189A2 (pt) | métodos de banco de células de alta densidade | |
EA201490945A1 (ru) | Набор, содержащий заменитель сыворотки и лабильные факторы | |
BR112015022529A2 (pt) | meios de cultura de células e processos de produção de anticorpo | |
BR112014003841A2 (pt) | estratégia de múltiplas cópias para produção em alto título e alta pureza de proteínas de múltiplas subunidades tal como anticorpos em micróbios transformados tal como pichia pastoris | |
BR112014000522A2 (pt) | meio de cultura, método para cultivar salmonella e e. coli e método para detectar salmonella e e. coli | |
BR112013020216A2 (pt) | Processo para produzir substância-alvo através do processo de fermentação | |
BR112014011198A2 (pt) | dispositivos e métodos para aumento da viabiliade de bactérias em forma de bastonete | |
BR112015014328A2 (pt) | Célula de mamífero capaz de propagar arterivírus, cultura celular, e, método para a propagação de um arterivírus em cultura celular | |
MX2015010887A (es) | Formulaciones y metodos para aumentar la produccion de proteinas recombinantes. | |
IN2014DN02050A (pt) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/09/2013, OBSERVADAS AS CONDICOES LEGAIS. |